Efinopegdutide clinical trial aims to demonstrate superior liver fat reduction compared to semaglutide in NAFLD

Nonalcoholic Fatty Liver Disease (NAFLD), encompassing simple steatosis to Nonalcoholic Steatohepatitis (NASH), is a growing global health concern, often progressing to cirrhosis, liver failure, and hepatocellular carcinoma. Current management primarily relies on lifestyle modifications, which are often insufficient for sustained improvement. There's an urgent need for effective pharmacological interventions to reduce hepatic fat and inflammation, thereby preventing disease progression. Peptides targeting metabolic pathways, such as GLP-1 receptor agonists, have shown promise in improving metabolic parameters and reducing liver fat, making them a focus for advanced NAFLD therapies.

This clinical trial (MK-6024-001) is designed to assess the efficacy of efinopegdutide in participants diagnosed with Nonalcoholic Fatty Liver Disease (NAFLD). The study's primary objective is to determine if efinopegdutide is superior to semaglutide in reducing liver fat content (LFC) from baseline after 24 weeks of treatment. The primary endpoint measures the mean relative reduction in LFC. The trial hypothesizes that efinopegdutide will either be superior to semaglutide or demonstrate superiority by at least 10% in LFC reduction, providing a direct comparison between these two peptide-based interventions.